HCW Biologics Inc. (HCWB) shareholders
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Hing C. Wong, Ph.D. | 501,911 | 23.38% | 13D (active) amendment | May 15, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HCWB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 52,138 | 2.84% | $260.17K | +49,782 | 0.00% |
| Citadel Advisors LLC | 19,942 | 1.09% | $99.51K | +15,595 | 0.00% |
| Hrt Financial LP | 13,583 | 0.74% | $67.00K | −30,816 | 0.00% |
| Vanguard Fiduciary Trust Co | 6,510 | 0.35% | $32.49K | +6,193 | 0.00% |
| Tower Research Capital LLC (TRC) | 4,117 | 0.22% | $20.54K | +1,643 | 0.00% |
| Connective Capital Management, LLC | 3,338 | 0.18% | $16.66K | New | 0.01% |
| Vanguard Capital Management LLC | 2,003 | 0.11% | $10.00K | −1 | 0.00% |
| Golden State Wealth Management, LLC | 1,667 | 0.09% | $8.32K | – | 0.00% |
| Barclays PLC | 191 | 0.01% | $953 | New | 0.00% |
| Caitong International Asset Management Co., Ltd | 11 | 0.00% | $10 | New | 0.00% |
| Osaic Holdings, Inc. | 4 | 0.00% | $20 | – | 0.00% |
| UBS Group AG | 1 | 0.00% | $5 | −1,536 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 12 | 0M | 5.6% | 3 / 4 | 3 / 6 | 0M | 0M |
| Q1 2026 | 15 | 0M | 4.1% | 7 / 5 | 0 / 5 | 0M | 0M |
| Q4 2025 | 14 | 0M | 4.0% | 5 / 2 | 3 / 1 | 0M | 0M |
| Q3 2025 | 10 | 0M | 1.1% | 4 / 1 | 1 / 2 | 0M | 0M |
| Q2 2025 | 8 | 0M | 0.2% | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held HCWB in Q2 2026, 27% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of HCWB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 2,004 | 0.11% | $10.00K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Hing C. Wong | Chief Executive Officer, Director, 10% owner | 125,845 | 6.85% | Jul 31, 2026 |
| Lee Flowers | SVP of Business Development | 8,691 | 0.47% | Jul 31, 2026 |
| Rebecca Byam | Chief Financial Officer | 57,245 | 3.12% | May 27, 2026 |
| Scott T. Garrett | Director | 67,149 | 3.66% | Jul 31, 2026 |
| Gary M. Winer | Director | 4,075 | 0.22% | May 20, 2025 |
| Rick S. Greene | Director | 2,066 | 0.11% | May 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lee Flowers SVP of Business Development | Jul 29, 2026 | Buy | +7,736 | $2.59 | $20.04K | 8,691 |
| Hing C. Wong Chief Executive Officer, Director, 10% owner | Jul 29, 2026 | Buy | +23,210 | $2.59 | $60.11K | 125,845 |
| Scott T. Garrett Director | Jul 29, 2026 | Buy | +7,736 | $2.59 | $20.04K | 41,644 |
| Scott T. Garrett Director | May 22, 2026 | Buy | +177,936 | $1.41 | $250.89K | 203,441 |
| Hing C. Wong Chief Executive Officer, Director, 10% owner | May 22, 2026 | Buy | +113,879 | $1.41 | $160.57K | 615,790 |
| Rebecca Byam Chief Financial Officer | May 22, 2026 | Buy | +14,235 | $1.41 | $20.07K | 57,245 |
| Gary M. Winer Director | May 16, 2025 | Buy | +1,342 | $7.45 | $10.00K | 4,075 |
| Hing C. Wong Chief Executive Officer, Director, 10% owner | May 16, 2025 | Buy | +8,054 | $7.45 | $60.00K | 501,911 |
| Scott T. Garrett Director | May 16, 2025 | Buy | +13,423 | $7.45 | $100.00K | 25,505 |
| Rebecca Byam Chief Financial Officer | May 8, 2025 | Buy | +8,462 | $26.00 | $220.01K | 43,010 |
| Scott T. Garrett Director | May 8, 2025 | Buy | +5,385 | $26.00 | $140.01K | 12,082 |
| Hing C. Wong Chief Executive Officer, Director, 10% owner | May 8, 2025 | Buy | +92,500 | $26.00 | $2.41M | 493,857 |
| Gary M. Winer Director | May 8, 2025 | Buy | +2,308 | $26.00 | $60.01K | 2,733 |
| Lee Flowers SVP of Business Development | May 8, 2025 | Buy | +962 | $26.00 | $25.01K | 5,720 |
| Rick S. Greene Director | May 8, 2025 | Buy | +962 | $26.00 | $25.01K | 2,066 |
| Hing C. Wong Chief Executive Officer, Director | Feb 20, 2024 | Award | +739,288 | $1.40 | $1.04M | 16,054,156 |
| Rick S. Greene Director | Feb 20, 2024 | Award | +35,714 | $1.40 | $50.00K | 44,125 |
| Scott T. Garrett Director | Feb 20, 2024 | Award | +142,858 | $1.40 | $200.00K | 267,858 |
| Rebecca Byam Chief Financial Officer | Feb 20, 2024 | Award | +760,714 | $1.40 | $1.06M | 1,381,909 |
| Lee Flowers SVP of Business Development | Feb 20, 2024 | Award | +71,429 | $1.40 | $100.00K | 190,238 |
| Lisa M. Giles Director | Feb 20, 2024 | Award | +35,715 | $1.40 | $50.00K | 35,815 |
| Peter Rhode See Remarks | Dec 11, 2023 | Option exercise | +14,000 | $0.14 | $1.96K | 77,500 |
| Lee Flowers SVP of Business Development | Dec 8, 2023 | Option exercise | +7,501 | $0.14 | $1.05K | 118,809 |
| Peter Rhode See Remarks | Nov 17, 2023 | Option exercise | +15,000 | $0.14 | $2.10K | 63,500 |
| Rebecca Byam Chief Financial Officer | Oct 19, 2023 | Option exercise | +47,249 | $0.14 | $6.61K | 621,195 |
| Hing C. Wong Chief Executive Officer, Director | Sep 14, 2023 | Buy | +1,800 | $2.08 | $3.74K | 15,314,868 |
| Gary M. Winer Director | Sep 14, 2023 | Buy | +162 | $2.08 | $337 | 16,121 |
| Gary M. Winer Director | Sep 14, 2023 | Buy | +879 | $2.05 | $1.80K | 17,000 |
| Gary M. Winer Director | Sep 13, 2023 | Buy | +46 | $2.00 | $92 | 15,959 |
| Gary M. Winer Director | Sep 13, 2023 | Buy | +500 | $2.05 | $1.03K | 15,913 |
| Rebecca Byam Chief Financial Officer | Sep 13, 2023 | Buy | +5,000 | $2.10 | $10.50K | 573,946 |
| Rebecca Byam Chief Financial Officer | Sep 12, 2023 | Buy | +5,000 | $2.09 | $10.45K | 568,946 |
| Gary M. Winer Director | Sep 12, 2023 | Buy | +500 | $2.05 | $1.03K | 15,413 |
| Rebecca Byam Chief Financial Officer | Sep 11, 2023 | Buy | +5,000 | $2.05 | $10.25K | 563,946 |
| Gary M. Winer Director | Sep 11, 2023 | Buy | +99 | $2.05 | $203 | 14,913 |
| Gary M. Winer Director | Sep 8, 2023 | Buy | +1 | $1.90 | $2 | 14,814 |
| Rebecca Byam Chief Financial Officer | Sep 8, 2023 | Buy | +5,000 | $2.02 | $10.10K | 558,946 |
| Rebecca Byam Chief Financial Officer | Sep 7, 2023 | Buy | +5,000 | $1.95 | $9.75K | 553,946 |
| Gary M. Winer Director | Sep 7, 2023 | Buy | +63 | $1.95 | $123 | 14,813 |
| Rebecca Byam Chief Financial Officer | Sep 6, 2023 | Buy | +5,000 | $1.95 | $9.75K | 548,946 |
| Gary M. Winer Director | Sep 5, 2023 | Buy | +400 | $1.75 | $700 | 14,750 |
| Rebecca Byam Chief Financial Officer | Jun 9, 2023 | Buy | +20,000 | $2.06 | $41.20K | 543,946 |
| Lee Flowers SVP of Business Development | Jun 8, 2023 | Option exercise | +5,356 | $0.14 | $750 | 101,308 |
| Lee Flowers SVP of Business Development | Jun 8, 2023 | Buy | +10,000 | $2.16 | $21.60K | 111,308 |
| Rebecca Byam Chief Financial Officer | Jun 8, 2023 | Buy | +4,696 | $2.21 | $10.38K | 523,946 |
| Rebecca Byam Chief Financial Officer | Jun 7, 2023 | Buy | +20,000 | $2.03 | $40.60K | 519,250 |
| Rebecca Byam Chief Financial Officer | Jun 6, 2023 | Buy | +19,062 | $1.82 | $34.69K | 499,250 |
| Rebecca Byam Chief Financial Officer | Jun 5, 2023 | Buy | +20,000 | $1.67 | $33.40K | 480,188 |
| Hing C. Wong Chief Executive Officer, Director | Jun 2, 2023 | Buy | +800 | $1.54 | $1.23K | 15,313,068 |
| Hing C. Wong Chief Executive Officer, Director | Jun 1, 2023 | Buy | +800 | $1.62 | $1.30K | 15,312,268 |
| Gary M. Winer Director | May 31, 2023 | Buy | +500 | $1.50 | $750 | 14,350 |
| Hing C. Wong Chief Executive Officer, Director | May 31, 2023 | Buy | +2,000 | $1.55 | $3.10K | 15,311,468 |
| Gary M. Winer Director | May 30, 2023 | Buy | +850 | $1.52 | $1.29K | 13,850 |
| Hing C. Wong Chief Executive Officer, Director | May 30, 2023 | Buy | +3,000 | $1.55 | $4.65K | 15,309,468 |
| Rebecca Byam Chief Financial Officer | May 26, 2023 | Buy | +20,000 | $1.66 | $33.20K | 460,188 |
| Rebecca Byam Chief Financial Officer | May 25, 2023 | Buy | +20,000 | $1.62 | $32.40K | 440,188 |
| Rebecca Byam Chief Financial Officer | May 24, 2023 | Buy | +20,000 | $1.61 | $32.20K | 420,188 |
| Rebecca Byam Chief Financial Officer | May 23, 2023 | Buy | +5,036 | $1.57 | $7.91K | 400,188 |
| Rebecca Byam Chief Financial Officer | May 22, 2023 | Buy | +33,450 | $1.53 | $51.18K | 395,152 |
| Rebecca Byam Chief Financial Officer | Nov 2, 2022 | Option exercise | +33,750 | $0.14 | $4.73K | 361,702 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of HCW Biologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 86,085 shares on Sep 25, 2026 over the last 90 days.
See a number that looks wrong?